Bertis Signs MOU with COSMAX for Joint Research in Skin Proteomics Analysis

-    Collaboration to begin with establishing skin proteomics analysis technology, expanding into joint development of skin biomarker panels and related business initiatives

-    Expanding the application of proteomics into personalized skin aging care

<Photo: From left, COSMAX Group Chairman Kyung-soo Lee, Bertis Co-CEO Dong-young Noh, and Bertis Co-CEO Seung-man Han pose for a commemorative photo during the MOU signing ceremony held at COSMAX’s headquarters in Seongnam, Gyeonggi Province, on April 11.>

On April 15, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced the signing of a memorandum of understanding (MOU) with COSMAX, a global leader in cosmetic ODM (Original Development and Manufacturing), to collaborate on research in skin proteomics analysis.

Under this MOU, the two companies plan to collaborate comprehensively in areas including academic exchange related to skin proteomics analysis technology, joint development of skin biomarker panels, and co-development, production, and commercialization of cosmetic ingredients and formulations.

Skin proteomics analysis utilizes advanced proteomic technologies to precisely identify and quantify proteins expressed in skin tissues or cells. This allows for the detailed understanding of physiological changes in the skin and its biological responses to external stimuli. It can be applied to diagnose skin aging, damage, regeneration, and irritation, as well as to develop personalized skincare and cosmetic solutions.

COSMAX, the world’s top cosmetic ODM company, possesses world-class capabilities in utilizing biological resources and was the first in the world to commercialize microbiome-based skincare in 2019. The collaboration will start with building a foundation for skin proteomics, with plans to expand into database construction, protein profiling by cause of aging, and diagnostic software development.

Seung-man Han, CEO of Bertis, stated, "We at Bertis possess unmatched expertise in discovering biomarkers for cancer, aging, and other major diseases through proteomics, and in developing diagnostic and analytical solutions based on those findings. We are excited to collaborate with COSMAX to advance our capabilities in skin proteomics and broaden the application of proteomics technology into personalized skin aging care."

Bertis is a leading company in commercializing proteomics technology based on its proprietary ProteoID platform, which spans from protein data analysis to product and service development. In 2019, the company launched MASTOCHECK®, the world’s first proteomics-based blood test for the early detection of breast cancer. Additionally, Bertis offers PASS (Pan-omics Analysis Service & Solution), an integrated omics analysis solution that provides customized results tailored to the needs of clients across the biotech and CDMO industries—from basic R&D to novel modality drug development.